Christopher Lee

Group Website

Address

Vision Statement

Dr.

Christopher Lee

Position

Clinical Assistant Professor

Division

Medical Oncology

Phone

Email

Overview
OpenClose

Research Interests

Research Summary

Research Highlights

Personal

Education and Affiliations
OpenClose

Education

B.Sc. First Class Honours Dalhousie University, Halifax NS Biology,

MD Dalhousie University, Halifax NS,

Residency Training University of Ottawa, Ottawa ON Internal Medicine,

Residency Training University of Ottawa, Ottawa ON Medical Oncology,

Affiliations

Publications and Awards
OpenClose

Recent Publications

  • Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 study. J Clin Oncol 2010; 28: 49-55.
  • Lee CW, Murray N, Anderson H, Rao SC, Bishop W. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 2009; 64: 308-313.
  • Bezjak A, Lee CW, Ding K, Brundage M, Winton T, Graham B, Whitehead M, Johnson DH, Livingston RB, Seymour L, Shepherd FA. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol 2008; 26: 5052-5059.
  • Lee CW, Belanger K, Rao SC, Petrella TM, Tozer RG, Wood L, Savage KJ, Eisenhauer EA, Synold TW, Wainman N, Seymour L. A phase II study of SB-715992 in patients with metastatic or recurrent malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group trial.  Invest New Drugs 2008; 26: 249-255.
  • Lee CW, Martin J, MacRae R, Tsao MS, Nguyen E, Johnston M, Baas P, Laurie S, Feld R, Murray N, Shepherd FA. Malignant mesothelioma: Canadian perspective and research directions. Curr Oncol 2008; 15: 62-69.
  • Arnold AA, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, Lee CW, Djurfeldt M, Whitehead M, Ellis P, Goss G, Chan A, Meharchand J, Alam Y, Gregg R, Butts C, Langmuir P, Shepherd F. Phase II trial of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group study BR.20. J Clin Oncol 2007; 25: 4278-4284.
  • Smylie MG, Wong R, Mihalcioiu C, Lee C, Pouliot J-F. A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma. Invest New Drugs 2007; 25: 155-159.

Awards & Recognition

Grants
OpenClose

Grants

Teaching/Students
OpenClose